In his Forbes article, Personal Finance Contributor Ted Knutson discussed Tuesday’s Senate Committee on Finance hearing that focused on climate change tax reform. During the hearing, leaders on both sides of the aisle asserted that new clean energy laws should be technology neutral, so that no one industry “wins.”
On fee.org, the website for the Foundation for Economic Education, author Brad Polumbo reported on Alex Brill’s estimates of the true cost of the American Rescue Plan.
Alex Brill was recently quoted in Rachel Bucchino’s article on nationalinterest.org, “Joe Biden Is Leading the Charge on a Big Global Tax Hike.” The article examines Treasury Secretary Janet Yellen’s work on a global minimum tax for multinational corporations.
This week, three publications in the healthcare policy and regulatory affairs industries referenced MGA’s recent report on the potential savings from accelerating US approval of complex generics.
“‘The nursing home COVID crisis in New York and New Jersey and Connecticut from the beginning of the pandemic, things are different and way better there. But as the pandemic is spreading throughout the country, we’re going to see it pop up in other nursing homes’ Brill said.”
“‘I think it creates confusion for the negotiators. Republicans on the Hill are looking for a signal from the president. They are looking for leadership on this, and he’s oscillating,’ Brill said.”
“The report finds that extending patents on just those five drugs [Prilosec, TriCor, Suboxone, Doryx, and Namenda] will result in a cost to the U.S. health care system of $4.7 billion annually—money that in theory could have been saved if the drugs had been available in a generic form.”
Brand-name Drugmaker Tactic ‘Product Hopping’ Costs US Healthcare System $4.7 Billion Annually, Study Says
“An anti-competitive tactic used by brand-name drugmakers called product hopping costs the U.S. healthcare system at least $4.7 billion annually, according to a study from Matrix Global Advisors.”
“But Alex Brill of the right-leaning American Enterprise Institute said Congress shouldn’t approve more costly economic recovery payments because they aren’t well targeted toward households directly impacted by the pandemic.”
“That’s an impossible bar to clear, writes Alex Brill, an economist with Matrix Global Advisors and a fellow at the American Enterprise Institute, in a new report sponsored by the PBM lobby Pharmaceutical Care Management Association.”